Avails Medical Inc., 1455 Adams Drive, Menlo Park, CA, 94025, USA.
Stanford University School of Medicine, 3375 Hillview Ave, Palo Alto, CA, 94304, USA.
Sci Rep. 2021 May 31;11(1):11360. doi: 10.1038/s41598-021-90830-2.
A key predictor of morbidity and mortality for patients with a bloodstream infection is time to appropriate antimicrobial therapy. Accelerating antimicrobial susceptibility testing from positive blood cultures is therefore key to improving patient outcomes, yet traditional laboratory approaches can require 2-4 days for actionable results. The eQUANT-a novel instrument utilizing electrical biosensors-produces a standardized inoculum equivalent to a 0.5 McFarland directly from positive blood cultures. This proof-of-concept study demonstrates that eQUANT inocula prepared from clinically significant species of Enterobacterales were comparable to 0.5 McF inocula generated from bacterial colonies in both CFU/ml concentration and performance in antimicrobial susceptibility testing, with ≥ 95% essential and categorical agreement for VITEK2 and disk diffusion. The eQUANT, combined with a rapid, direct from positive blood culture identification technique, can allow the clinical laboratory to begin antimicrobial susceptibility testing using a standardized inoculum approximately 2-3 h after a blood culture flags positive. This has the potential to improve clinical practice by accelerating conventional antimicrobial susceptibility testing and the resulting targeted antibiotic therapy.
血流感染患者发病率和死亡率的一个关键预测因素是及时给予适当的抗菌治疗。因此，加速从阳性血培养物中进行抗菌药物敏感性检测对于改善患者预后至关重要，然而传统的实验室方法可能需要 2-4 天才能获得可行的结果。eQUANT 是一种新型仪器，利用电生物传感器从阳性血培养物中直接产生标准化接种物，相当于 0.5 麦氏比浊度。这项概念验证研究表明，eQUANT 接种物由肠杆菌科具有临床意义的物种制备，与从细菌菌落生成的 0.5 McF 接种物在 CFU/ml 浓度和抗菌药物敏感性测试中的性能相当，VITEK2 和纸片扩散法的主要和分类一致性均≥95%。eQUANT 与一种快速、直接从阳性血培养物中进行鉴定的技术相结合，可以使临床实验室在血培养物阳性后大约 2-3 小时开始使用标准化接种物进行抗菌药物敏感性测试。这有可能通过加速常规抗菌药物敏感性测试和随后的靶向抗生素治疗来改善临床实践。
